Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/31637
Title: Production of interleukin-10 in asthmatic children after Beta-1-3-glucan
Authors: Sarinho, E.
Medeiros, D.
Schor, D.
Silva, A. Rego
Sales, V.
Motta, M. E.
Costa, A.
Azoubel, A. [UNIFESP]
Rizzo, J. A.
Universidade Federal de Pernambuco (UFPE)
Univ Fed Rio Grande do Sul
Universidade Federal de São Paulo (UNIFESP)
Keywords: Allergy
Asthma. Glucan
Immunomodulation
Interleukin-10
Issue Date: 1-Jul-2009
Publisher: Elsevier B.V.
Citation: Allergologia Et Immunopathologia. Barcelona: Elsevier Doyma Sl, v. 37, n. 4, p. 188-192, 2009.
Abstract: Background: Beta-1-3 Glucan is a polysaccharide extracted from Saccharomyces cerevisiae with a possible immunomodulating action that may have a favourable action on asthma symptoms and other allergic diseases. An experimental study carried out using a murine respiratory model detected a decrease in pulmonary tissue eosinophilia, as well as an increase in Interleukin-10 (IL-10) after glucan use.Methods: This open, exploratory study with blind outcome evaluation included asthmatic children between 6 and 12 years of age with mild to moderate persistent asthma and inadequate disease control (rescue medication needed more than twice a week) in spite of inhaled budesonide 400 mu g/day. After a four week run-in period, subcutaneous Beta-1-3-glucan injections were given weekly for the first four weeks and then every two weeks for the last four weeks. IL-10 levels, measured by the immunoenzymatic method (ELISA), were compared before and after glucan administration.Results: Twenty patients (14 male and 6 female) were included. Mean IL-10 levels were 6.4 pg/ml and 11.3 pg/ml before and after glucan, respectively (p = 0.02). There was also a reduction of asthmatic symptoms score at the end of study.Conclusions: This is the first study which shows that subcutaneous particulate Beta-1-3-glucan increases serum IL-10 levels in asthmatics. the possibility of glucan being able to modulate allergic sensitisation and having a beneficial action in restoring Th2 function should be assessed by means of property planned controlled clinical trials, as it may represent a new therapeutic strategy. (C) 2008 SEICAP. Published by Elsevier Espana, S.L. All rights reserved.
URI: http://repositorio.unifesp.br/handle/11600/31637
ISSN: 0301-0546
Other Identifiers: http://dx.doi.org/10.1016/j.aller.2009.02.005
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.